Table 2 The subtype distribution of the ART failures patients from 2012 to 2017. and the different drug resistance classes (single/double/ Triple drug resistance) in these patients
Year | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | total |
|---|---|---|---|---|---|---|---|
ART Failure | 130 | 303 | 585 | 675 | 703 | 536 | 2932 |
Obtained sequence | 112 | 239 | 508 | 511 | 528 | 397 | 2295 |
Subtype | |||||||
AE | 75 (66.96%) | 163 (68.20%) | 355 (69.88%) | 365 (71.43%) | 294 (55.68%) | 220 (55.42%) | 1472 (64.14%) |
BC | 11 (9.82%) | 26 (10.88%) | 80 (15.75%) | 106 (20.74%) | 115 (21.78%) | 73 (18.39%) | 411 (17.91%) |
B | 21 (18.75) | 37 (15.48%) | 52 (10.24%) | 30 (5.87%) | 66 (12.50%) | 58 (14.61%) | 264 (11.50%) |
C | 4 (3.57) | 13 (5.44%) | 20 (3.94%) | 9 (1.76%) | 23 (4.53%) | 12 (3.02%) | 81 (3.53%) |
Other | 1 (0.89%) | 0 | 1 (0.20%) | 1 (0.20%) | 30 (5.68%) | 34 (8.56%) | 67 (2.92%) |
DRMs | 42 | 84 | 201 | 215 | 209 | 163 | Â |
Only PI | 0 | 0 | 1 | 3 | 4 | 2 | 10 |
Only NRTI | 1 | 1 | 13 | 6 | 21 | 7 | 49 |
Only NNRTI | 6 | 23 | 57 | 56 | 50 | 29 | 221 |
PI and NRTI | 0 | 0 | 0 | 1 | 1 | 2 | 4 |
PI and NNRTI | 0 | 0 | 0 | 0 | 3 | 1 | 4 |
NRTI and NNRTI | 35 | 60 | 129 | 144 | 121 | 94 | 583 |
PI and NRTI and NNRTI | 0 | 0 | 1 | 5 | 9 | 28 | 43 |